T. Rowe Price Investment Management Inc. Buys 5,213,370 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT)

T. Rowe Price Investment Management Inc. raised its holdings in Applied Therapeutics, Inc. (NASDAQ:APLT - Free Report) by 2,511.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 5,420,920 shares of the company's stock after acquiring an additional 5,213,370 shares during the quarter. T. Rowe Price Investment Management Inc. owned about 4.66% of Applied Therapeutics worth $4,642,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of APLT. Private Advisor Group LLC bought a new position in shares of Applied Therapeutics in the 4th quarter worth $35,000. SG Americas Securities LLC grew its position in shares of Applied Therapeutics by 169.0% during the 4th quarter. SG Americas Securities LLC now owns 40,747 shares of the company's stock worth $35,000 after buying an additional 25,601 shares during the period. Intech Investment Management LLC increased its stake in shares of Applied Therapeutics by 176.1% in the 4th quarter. Intech Investment Management LLC now owns 52,631 shares of the company's stock valued at $45,000 after acquiring an additional 33,567 shares during the last quarter. Dark Forest Capital Management LP raised its position in shares of Applied Therapeutics by 54.5% in the 4th quarter. Dark Forest Capital Management LP now owns 53,718 shares of the company's stock valued at $46,000 after acquiring an additional 18,949 shares during the period. Finally, Legal & General Group Plc boosted its stake in Applied Therapeutics by 293.9% during the 4th quarter. Legal & General Group Plc now owns 84,018 shares of the company's stock worth $72,000 after acquiring an additional 62,686 shares during the last quarter. Institutional investors and hedge funds own 98.31% of the company's stock.

Applied Therapeutics Stock Performance

NASDAQ:APLT traded up $0.05 during trading hours on Friday, hitting $0.46. The stock had a trading volume of 3,882,182 shares, compared to its average volume of 3,209,294. The business's 50 day moving average is $0.44 and its 200-day moving average is $2.49. The company has a market cap of $65.18 million, a price-to-earnings ratio of -0.29 and a beta of 2.00. Applied Therapeutics, Inc. has a one year low of $0.30 and a one year high of $10.62.

Applied Therapeutics (NASDAQ:APLT - Get Free Report) last released its quarterly earnings data on Monday, April 14th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.06). The company had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.61 million. On average, sell-side analysts anticipate that Applied Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.